IBX

IMAGIONBIO FPO [IBX]
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry. The company has collaboration agreement with Wayne State University to develop optimised MRI sequences which is in Phase 2 study of for the MagSense imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0080 -11.1%

Updated 3 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when IBX triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track IBX — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is losing steam
  • Volume surging at 4.9x normal while price falls — heavy selling pressure
  • Took a hit — down 11.1% over the last 5 days
  • Lagging the Small Ords index — relative strength of 0.63, underperforming its peers
  • Critical cash runway (0.0 quarters)
  • Moderate P/S ratio (11.2x)
  • Strong revenue growth (+1944%)
  • Near 52-week low (2% of range)
  • Micro-cap ($5-20M) - high risk
  • Capital raise activity (1 events)
  • CANSLIM S: Tight float (48%)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +1944% — the top line is moving in the right direction
  • Altman Z-Score distress zone (0.12 < 1.81, low-confidence approx)
  • Penny stock risk ($0.008)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 38% over the past year
  • The bigger volume days are the down days — volume-weighted momentum is negative (-4.99%/day)
Ask Scout AI about IBX
"What's driving IBX today?" "How does IBX compare to peers?" "Key risks for IBX?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Cleansing Notice
NONE Application for quotation of securities - IBX
NONE Application for quotation of securities - IBX
MEDIUM IBX Phase 2 Clinical Trial Update

Recent ASX Announcements

2026-09-01 Cleansing Notice
2026-09-01 Application for quotation of securities - IBX
2026-08-31 Application for quotation of securities - IBX
2026-08-27 Notification of cessation of securities - IBX
2026-08-25 IBX Phase 2 Clinical Trial Update PRICE SENSITIVE

Key Metrics

$6.4M
Market Cap
2.7M
Avg Volume
4.9x
Vol Ratio
$0.01 — $0.06
52-Week Range
N/A
Short Interest
N/A
Cash Runway
N/A
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 48%
LLeader vs LaggardlaggardRS: -25
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

113 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
REG -27.0%CAN +25.0%BIT -20.0%MEM +20.0%CMP -14.6%
Compare:IBX vs REGIBX vs CANIBX vs BIT
Scout Pro — Deeper Analysis for IBX
Try Pro free for 30 days
Share this analysis

Track IBX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required